|
 The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged all its member exporters to participate in the Export-Import Bank of India’s (EXIM Bank) Annual Exporter Survey 2025. The survey is a key initiative aimed at strengthening India’s trade policies through first hand exporter insights.
EXIM Bank is a specialized financial institution wholly owned by the Government of India. Its primary mandate is to finance, facilitate, and promote India’s international trade. As the principal financial institution coordinating export and import financing activities, EXIM Bank plays a crucial role in advancing the country’s global trade engagement.
In line with this mandate, EXIM Bank is conducting its Annual Survey of Exporters to gather valuable insights on export trends, challenges, and opportunities. The survey findings will support evidence-based policymaking and contribute to improved trade facilitation measures.
The objective is to capture ground-level perspectives from pharma exporters on the current trade environment, sector-specific challenges, and emerging opportunities.
“All member exporters have been urged to participate in this important initiative by completing the survey. These inputs are highly valuable, as they will help shape policies and strategies that directly benefit the export community,” said Raja Bhanu, director general of Pharmexcil, in an official statement released on Monday.
The data collected through the survey will form the backbone of evidence-based policymaking. It is expected to play a significant role in influencing national trade policies, export credit frameworks, and regulatory reforms aimed at simplifying export procedures.
The pharmaceutical sector, which has consistently contributed to India’s export growth, is a vital stakeholder in this initiative. Pharmexcil, functioning under the ministry of commerce & industry, has reiterated the importance of the survey in capturing critical information about export barriers, logistics issues, compliance challenges, and market access difficulties.
“This survey provides a unique platform for exporters to voice their concerns and recommendations directly to policymakers. The pharmaceutical industry, with its vast international outreach and regulatory complexities, stands to gain immensely by participating,” the Pharmexcil DG added.
EXIM Bank officials have emphasized that the Annual Exporter Survey is not merely a data collection exercise, but a strategic policy tool. It helps calibrate the bank’s financial offerings, including lines of credit, buyer’s credit, and export credit insurance, based on real-world exporter experiences.
Over the years, insights from the survey have contributed to enhanced export credit support mechanisms, simplified documentation procedures, sector-specific support for MSME exporters and identification of emerging export markets and sectors
India’s pharmaceutical exports reached USD 27.9 billion in FY 2024, positioning the country among the top exporters of generic medicines worldwide. As global healthcare systems evolve post-pandemic, Indian pharmaceutical exporters are exploring new geographies, expanding product portfolios, and aligning with stricter regulatory environments.
However, with growing competition, supply chain disruptions, and shifting trade policies globally, Indian exporters face a complex landscape. The EXIM Bank’s survey is expected to surface these nuanced challenges and enable the government to offer more targeted interventions.
Pharmexcil has shared that the survey is accessible online and can be completed in a few minutes. The EXIM Bank has assured that all responses will be kept confidential and used solely for analytical and policy formulation purposes.
A strong representation from the pharmaceutical industry is expected and encouraged, given the sector's significant contribution to India’s overall export performance. Such collaborative feedback mechanisms are essential for bridging policy gaps, identifying pharma sector-specific incentives, and optimizing financial and institutional support systems.
|